Wo Wu Biological: First Subject Enrolled in Phase II Clinical Trial of House Dust Mite Membrane Agent

Wo Wu Biologics announced that the first participant has been enrolled in the affiliated Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, for the clinical study evaluating the efficacy and safety of the company’s R&D product “House Dust Mite Membrane Preparation,” administered sublingually, in Chinese adult patients with dust mite allergic rhinitis— a randomized, double-blind, placebo-controlled Phase II clinical trial— and the study has officially entered the clinical trial phase.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin